James O'Brien

James O'Brien

Finanzdirektor/CFO bei MESOBLAST LIMITED
59 Jahre
Health Technology
Commercial Services
Consumer Services

Profil

James M.
O'Brien
is currently Chief Financial Officer at Mesoblast Ltd. since 2025.
Former positions include Chief Financial Officer at Faron Pharmaceuticals Oy from 2023 to 2024, Chief Financial Officer at Cognition Therapeutics, Inc. from 2019 to 2022, Executive Vice President-Finance at Enzo Biochem, Inc. from 2014 to 2019, Vice President & Corporate Controller at Allergan UC from 2010 to 2013, Vice President at Takeda Pharmaceutical Co., Ltd. in 2010, Chief Accounting Officer at U.S.I.
Holdings Corp.
from 2008 to 2009, Vice President & Controller at Aptuit LLC from 2005 to 2007, Chief Accountant at Purdue Pharma LP, and Principal at both Bristol Myers Squibb Co. and PricewaterhouseCoopers LLP.
Education includes undergraduate studies at George Washington University and an MBA from Fordham University.

Aktive Positionen von James O'Brien

UnternehmenPositionBeginn
MESOBLAST LIMITED Finanzdirektor/CFO 17.11.2025

Ehemalige bekannte Positionen von James O'Brien

UnternehmenPositionEnde
FARON PHARMACEUTICALS OY Finanzdirektor/CFO 15.04.2024
COGNITION THERAPEUTICS, INC. Finanzdirektor/CFO 12.08.2022
ENZO BIOCHEM, INC. Corporate Officer/Principal 03.11.2019
ALLERGAN PLC Comptroller/Controller/Auditor -
TAKEDA PHARMACEUTICAL COMPANY LIMITED Corporate Officer/Principal 01.08.2010
Sehen Sie sich die Erfahrung von James O'Brien im Detail an

Ausbildung von James O'Brien

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

28

Beziehungen ersten Grades

13

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen13

Health Technology

Health Technology

Commercial Services

Finance

Commercial Services

Health Technology

Consumer Services

Distribution Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Börse
  2. Insiders
  3. James O'Brien